Valproate attenuates the development of morphine antinociceptive tolerance

Neuroscience Letters

Volumn 485, Issue 2, 2010, Pages 125-128

  Dobashi, Tamae ^a   Tanabe, Serabi ^a   Jin, Hisayo ^a   Nishino, Takashi ^a   Aoe, Tomohiko ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glycogen synthase kinase; Mood stabilizer; Morphine tolerance; Opioid

Indexed keywords

4 AMINOBUTYRIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; MORPHINE; VALPROIC ACID;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; HOT PLATE TEST; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THERMAL INJURY;

ANALGESICS; ANIMALS; DRUG TOLERANCE; GABA AGENTS; GLYCOGEN SYNTHASE KINASE 3; HOT TEMPERATURE; MALE; MICE; MICE, INBRED C57BL; MORPHINE; MORPHINE DEPENDENCE; PAIN MEASUREMENT; PAIN THRESHOLD; VALPROIC ACID;

EID: 77957350620     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.08.084     Document Type: Article

References (27)

1. Bagley E.E., Chieng B.C., Christie M.J., Connor M. Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br. J. Pharmacol. 2005, 146:68-76.
2. Bielecka A.M., Obuchowicz E. Antiapoptotic action of lithium and valproate. Pharmacol. Rep. 2008, 60:771-782.
3. Bilecki W., Wawrzczak-Bargiela A., Przewlocki R. Activation of AP-1 and CRE-dependent gene expression via mu-opioid receptor. J. Neurochem. 2004, 90:874-882.
4. Boyle W.J., Smeal T., Defize L.H., Angel P., Woodgett J.R., Karin M., Hunter T. Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity. Cell 1991, 64:573-584.
5. Chakrabarti S., Regec A., Gintzler A.R. Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure. Brain Res. Mol. Brain Res. 2005, 135:217-224.
6. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
7. T. Dobashi, S. Tanabe, H. Jin, N. Mimura, T. Yamamoto, T. Nishino, T. Aoe, BiP, an endoplasmic reticulum chaperone, modulates the development of morphine antinociceptive tolerance, J. Cell Mol. Med., doi:10.1111/j.1582-4934.2009.00932.
8. Fang X., Yu S.X., Lu Y., Bast R.C., Woodgett J.R., Mills G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11960-11965.
9. Finn A.K., Whistler J.L. Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron 2001, 32:829-839.
10. Goode N., Hughes K., Woodgett J.R., Parker P.J. Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes. J. Biol. Chem. 1992, 267:16878-16882.
11. Granados-Soto V., Kalcheva I., Hua X., Newton A., Yaksh T.L. Spinal PKC activity and expression: role in tolerance produced by continuous spinal morphine infusion. Pain 2000, 85:395-404.
12. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 2001, 65:391-426.
13. Hartigan J.A., Johnson G.V. Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway. J. Biol. Chem. 1999, 274:21395-21401.
14. Kim A.J., Shi Y., Austin R.C., Werstuck G.H. Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 2005, 118:89-99.
15. Kim L., Liu J., Kimmel A.R. The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 1999, 99:399-408.
16. Lesort M., Jope R.S., Johnson G.V. Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 1999, 72:576-584.
17. Liu S., Yu S., Hasegawa Y., Lapushin R., Xu H.J., Woodgett J.R., Mills G.B., Fang X. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J. Biol. Chem. 2004, 279:51075-51081.
18. McElroy S.L., Keck P.E., Pope H.G., Hudson J.I. Valproate in psychiatric disorders: literature review and clinical guidelines. J. Clin. Psychiatry. 1989, 50(Suppl.):23-29.
19. Morgan M.M., Fossum E.N., Levine C.S., Ingram S.L. Antinociceptive tolerance revealed by cumulative intracranial microinjections of morphine into the periaqueductal gray in the rat. Pharmacol. Biochem. Behav. 2006, 85:214-219.
20. Parkitna J.R., Obara I., Wawrzczak-Bargiela A., Makuch W., Przewlocka B., Przewlocki R. Effects of glycogen synthase kinase 3beta and cyclin-dependent kinase 5 inhibitors on morphine-induced analgesia and tolerance in rats. J. Pharmacol. Exp. Ther. 2006, 319:832-839.
21. Quillan J.M., Carlson K.W., Song C., Wang D., Sadee W. Differential effects of mu-opioid receptor ligands on Ca(2+) signaling. J. Pharmacol. Exp. Ther. 2002, 302:1002-1012.
22. Rosenberg G. The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees?. Cell Mol. Life Sci. 2007, 64:2090-2103.
23. Solecki W., Krowka T., Kubik J., Kaczmarek L., Przewlocki R. Increased analgesic tolerance to acute morphine in fosB knock-out mice: a gender study. Pharmacol. Biochem. Behav. 2008, 90:512-516.
24. Somogyi A.A., Barratt D.T., Coller J.K. Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 2007, 81:429-444.
25. Sutherland C., Leighton I.A., Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 1993, 296(Pt 1):15-19.
26. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991, 251:85-87.
27. Yaksh T.L., Yeung J.C., Rudy T.A. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res. 1976, 114:83-103.